<DOC>
	<DOCNO>NCT02106845</DOCNO>
	<brief_summary>Evaluate effect regorafenib pharmacokinetics digoxin ( P-gp substrate : P-glycoprotein ) rosuvastatin ( BCRP substrate : Breast cancer resistant protein ) compare Area time curve ( AUC ( 0-24 ) ) maximum drug concentration ( Cmax ) Day -7 Cycle 1 Cycle 2 Day 15 regorafenib cancer patient</brief_summary>
	<brief_title>Effect Regorafenib Digoxin Rosuvastatin Patients With Advanced Solid Malignant Tumors .</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>The following criterion apply ALL patient start study treatment : Patients histologically confirm , locally advanced metastatic solid tumor refractory standard therapy regorafenib consider standard treatment . Male Female Caucasian patient &gt; /= 18 year age Women childbearing potential men must agree use adequate contraception enter program least 8 week last study drug administration . Life expectancy leat 12 week Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Adequate bone marrow liver function Estimated creatinine clearance ( CLcr ) â‰¥ 30 mL/min calculate use CockroftGault ( CG ) equation . Thyroid Stimulating Hormone ( TSH ) within normal range . The following inclusion criterion apply Group A ( digoxin + regorafenib ) patient ONLY : Potassium , magnesium calcium blood level within normal range accord local laboratory . The following inclusion criterion apply Group B ( rosuvastatin + regorafenib ) patient ONLY : Signed genetic informed consent . Patients must able understand willing sign write informed consent intend screen BCRP OATP1B1 polymorphism . For ALL patient Major surgical procedure , open biopsy , significant traumatic injury within 28 day start study medication . Nonhealing wound , skin ulcer , bone fracture . Ongoing active infection . Other anticancer treatment . Patients unable swallow oral medication For Group A ( digoxin + regorafenib ) : Family history sudden cardiac death . For Group B ( rosuvastatin + regorafenib ) : Patients porphyria . Patients intestinal urinary obstruction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>Probe substrate</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Cancer</keyword>
	<keyword>Safety</keyword>
	<keyword>Advanced solid malignant tumor</keyword>
</DOC>